660 related articles for article (PubMed ID: 34032121)
1. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
4. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
Diabetologia; 2024 Jul; 67(7):1328-1342. PubMed ID: 38509341
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
7. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
Cardiovasc Diabetol; 2024 Feb; 23(1):57. PubMed ID: 38331813
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
Arbel R; Hammerman A; Azuri J
Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890
[TBL] [Abstract][Full Text] [Related]
10. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.
Shao SC; Chang KC; Lin SJ; Chang SH; Hung MJ; Chan YY; Lai EC
Cardiovasc Diabetol; 2021 Oct; 20(1):213. PubMed ID: 34688282
[TBL] [Abstract][Full Text] [Related]
11. Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden.
Svanström H; Ueda P; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
Lancet Diabetes Endocrinol; 2019 Feb; 7(2):106-114. PubMed ID: 30527909
[TBL] [Abstract][Full Text] [Related]
12. Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
Grabarczyk TR; Wissman NK
Ann Pharmacother; 2020 Oct; 54(10):981-987. PubMed ID: 32274930
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE;
N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Norhammar A; Bodegård J; Nyström T; Thuresson M; Nathanson D; Eriksson JW
Diabetes Obes Metab; 2019 May; 21(5):1136-1145. PubMed ID: 30609272
[TBL] [Abstract][Full Text] [Related]
18. Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Shao SC; Chang KC; Hung MJ; Yang NI; Chan YY; Chen HY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2019 Sep; 18(1):120. PubMed ID: 31551068
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Patorno E; Pawar A; Wexler DJ; Glynn RJ; Bessette LG; Paik JM; Najafzadeh M; Brodovicz KG; Déruaz-Luyet A; Schneeweiss S
Diabetes Obes Metab; 2022 Mar; 24(3):442-454. PubMed ID: 34729891
[TBL] [Abstract][Full Text] [Related]
20. Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes.
Edmonston D; Mulder H; Lydon E; Chiswell K; Lampron Z; Shay C; Marsolo K; Jones WS; Butler J; Shah RC; Chamberlain AM; Ford DE; Gordon HS; Hwang W; Chang A; Rao A; Bosworth HB; Pagidipati N
Am J Cardiol; 2024 Jun; 221():52-63. PubMed ID: 38641191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
